Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
NKT2152
DRUG
2 trials
Sponsors
Hoffmann-La Roche
, NiKang Therapeutics, Inc.
Conditions
Adenocarcinoma
Advanced Liver Cancers
Advanced Renal Cell Carcinoma
Carcinoma
Carcinoma, Renal Cell
Clear Cell Renal Cell Carcinoma
Kidney Cancer
Kidney Diseases
+14 more
Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Recruiting
NCT04524871
Hoffmann-La Roche
Advanced Liver Cancers
Start: 2020-11-01
End: 2027-12-31
Target: 518
Updated: 2026-03-27
Phase 2
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Terminated
NCT05935748
NiKang Therapeutics, Inc.
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma +18
Start: 2023-07-28
End: 2025-09-04
Updated: 2025-11-12
Related Papers
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
2025-01-21
41 citations
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Cancer Research Communications
2024-03-29
14 citations
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Journal for ImmunoTherapy of Cancer
2023-06-01
83 citations
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology
2023-06-01
49 citations